Dynamic heterogeneity in COVID-19: Insights from a mathematical model
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0301780 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Chrysovalantis Voutouri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Edwin L Steele Laboratories, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States o…. Hauptthemen laut MEDLINE: COVID-19, Viral Load, SARS-CoV-2, Models, Theoretical. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, H2020 Marie Skłodowska-Curie Actions.
Abstract (Originalsprache)
Critical illness, such as severe COVID-19, is heterogenous in presentation and treatment response. However, it remains possible that clinical course may be influenced by dynamic and/or random events such that similar patients subject to similar injuries may yet follow different trajectories. We deployed a mechanistic mathematical model of COVID-19 to determine the range of possible clinical courses after SARS-CoV-2 infection, which may follow from specific changes in viral properties, immune properties, treatment modality and random external factors such as initial viral load. We find that treatment efficacy and baseline patient or viral features are not the sole determinant of outcome. We found patients with enhanced innate or adaptive immune responses can experience poor viral control, resolution of infection or non-infectious inflammatory injury depending on treatment efficacy and initial viral load. Hypoxemia may result from poor viral control or ongoing inflammation despite effective viral control. Adaptive immune responses may be inhibited by very early effective therapy, resulting in viral load rebound after cessation of therapy. Our model suggests individual disease course may be influenced by the interaction between external and patient-intrinsic factors. These data have implications for the reproducibility of clinical trial cohorts and timing of optimal treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Edwin L Steele Laboratories, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America.
- Department of Mechanical and Manufacturing Engineering, Cancer Biophysics Laboratory, University of Cyprus, Nicosia, Cyprus.
- Department of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America.
- Department of Medicine, Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, United States of America.
- Dana-Farber Cancer Institute, Boston, MA, United States of America.
- Center for the AIDS Programme of Research in South Africa, Durban, South Africa.
ORCID-Profile: Chrysovalantis Voutouri, Triantafyllos Stylianopoulos
Förderung
- NINDS NIH HHS
- NCI NIH HHS
- H2020 Marie Skłodowska-Curie Actions
- HORIZON EUROPE European Research Council
- RO1
- U01
Zitieren
APA
Voutouri, C., Hardin, C. C., Naranbhai, V., Nikmaneshi, M. R., Khandekar, M. J., Gainor, J. F., Munn, L. L., Jain, R. K., & Stylianopoulos, T. (2024). Dynamic heterogeneity in COVID-19: Insights from a mathematical model. PLOS ONE. https://doi.org/10.1371/journal.pone.0301780
Vancouver
Voutouri C, Hardin CC, Naranbhai V, Nikmaneshi MR, Khandekar MJ, Gainor JF, et al. Dynamic heterogeneity in COVID-19: Insights from a mathematical model. PLOS ONE. 2024. doi:10.1371/journal.pone.0301780
BibTeX
@article{Voutouri2024,
author = {Voutouri, Chrysovalantis and Hardin, C Corey and Naranbhai, Vivek and Nikmaneshi, Mohammad R and Khandekar, Melin J and Gainor, Justin F and Munn, Lance L and Jain, Rakesh K and Stylianopoulos, Triantafyllos},
title = {Dynamic heterogeneity in COVID-19: Insights from a mathematical model},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0301780}
}
EUVIMED